{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-135669","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2026-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.506314+00:00","generated_at":"2026-05-15T07:58:33.577830+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Axsome acquires global rights to PDE10A inhibitor balipodect from Takeda","bullets":["Obtained exclusive worldwide rights to balipodect, a selective PDE10A inhibitor, from Takeda.","Balipodect completed a 164-patient Phase 2 trial in schizophrenia; safety profile established in over 360 individuals.","Axsome plans to start Phase 3-enabling activities for schizophrenia in 2026 and also target Tourette syndrome.","Takeda received an upfront payment and is eligible for development, regulatory, and commercial milestones plus royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-135669","json":"https://secwatch.observer/filing/0001193125-26-135669.json","markdown":"https://secwatch.observer/filing/0001193125-26-135669.md","text":"https://secwatch.observer/filing/0001193125-26-135669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526135669/0001193125-26-135669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526135669/axsm-20260401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:58:33.577830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}